Glutamate carboxypeptidase II (GCPII, EC 3.4.17.21) is a membrane peptidase expressed in a number of tissues such as kidney, prostate and brain. The brain form of GCPII (also known as NAALADase) cleaves N-acetyl-aspartyl glutamate to yield free glutamate. Animal model experiments show that inhibition of GCPII prevents neuronal cell death during experimental ischaemia. GCPII thus represents an important target for the treatment of neuronal damage caused by excess glutamate. In this paper we report expression of an extracellular portion of human glutamate carboxypeptidase II (amino acids 44±750) in Drosophila Schneider's cells and its puri®-cation to homogeneity. A novel assay for hydrolytic activity of recombinant human GCPII (rhGCPII), based on¯uorimetric detection of released alpha-amino groups was established, and used for its enzymological characterization. rhGCPII does not show dipeptidylpeptidase IV-like activity assigned to the native form of the enzyme previously. Using a complete set of protected dipeptides, substrate speci®city of rhGCPII was elucidated. In addition to the previously described substrates, four novel compounds, Ac-Glu-Met, Ac-Asp-Met and, surprisingly, Ac-Ala-Glu and Ac-Ala-Met were identi®ed as substrates for GCPII, and their respective kinetic constants determined. The glycosylation of rhGCPII was found indispensable for the enzymatic activity. Keywords: enzyme glycosylation, glutamate carboxypeptidase II, NAALADase, neuroprotection, zinc metallopeptidase. Membrane glutamate carboxypeptidase II (GCPII) is a metalloproteinase expressed in various tissues and organs (Berger et al. 1995; Chang et al. 1999) . Its proteolytic activity was ®rstly recognized in brain cells, where it has been shown to be responsible for the cleavage of N-acetyl-Laspartyl-L-glutamate (NAAG) yielding free glutamate in the extracellular space. Based on the initial characterization of its substrate speci®city, the enzyme was termed N-acetylated alpha-linked-acidic-dipeptidase (NAALADase; Robinson et al. 1987) .
Membrane glutamate carboxypeptidase II (GCPII) is a metalloproteinase expressed in various tissues and organs (Berger et al. 1995; Chang et al. 1999) . Its proteolytic activity was ®rstly recognized in brain cells, where it has been shown to be responsible for the cleavage of N-acetyl-Laspartyl-L-glutamate (NAAG) yielding free glutamate in the extracellular space. Based on the initial characterization of its substrate speci®city, the enzyme was termed N-acetylated alpha-linked-acidic-dipeptidase (NAALADase; Robinson et al. 1987) .
NAAG is an abundant neuropeptide found in millimolar concentrations in the brain (Coyle 1997) . It is a mixed agonist/antagonist at N-methyl-D-aspartate ionotropic receptors and an agonist at the group II metabotropic glutamate receptors (mGlu; Wroblewska et al. 1993 Wroblewska et al. , 1997 . After release from pre-synaptic terminals, NAAG diffuses from the synaptic cleft and is rapidly hydrolysed by GCPII located on adjacent astrocytes. Free glutamate subsequently acts at the various glutamate receptor subtypes. Excessive receptor activation by glutamate is thought to be at least partially responsible for the neuronal injury caused by stroke (Fagg and Foster 1986) . Inhibition of NAAG metabolism was suggested as a possible strategy to attenuate excitatory amino acid transmission and to provide neuroprotection during cerebral ischaemia (Tortella et al. 2000) . Slusher et al. (1999) showed that inhibition of GCPII by the speci®c inhibitor 2-(phosphonomethyl)pentanedioic acid (2-PMPA) robustly protects against ischaemic injury in a tissue culture model of stroke and in rats after transient middle cerebral artery occlusion. The inhibitor increases NAAG concentration and attenuates the ischaemia-induced rise in glutamate concentration. Both effects apparently contribute to neuroprotection. GCPII has been thus shown to represent a plausible target for treatment of neurological disorders in which excessive glutamate transmission is pathogenic.
The second form of carboxypeptidase activity of GCPII is that of pteroylpoly gamma-glutamate carboxypeptidase. This activity was ®rst characterized from the brush border of intestinal mucosa where it converts pteroylpoly gammaglutamate to the pteroylglutamate (folate) form that is available for intestinal uptake (Pinto et al. 1996) . The activity was assigned to prostate-speci®c membrane antigen (PSMA), a known prostate cancer marker. The pteroylpoly gamma-glutamate carboxypeptidase activity of PSMA is responsible for the cleavage of methotrexatepolyglutamate and is thus important for its uptake and metabolism (Heston 1997) .
Both NAALADase and pteroylpoly gamma-glutamate carboxypeptidase activities have been assigned to a single membrane protein, PSMA (Pinto et al. 1996) , and the new name for the enzyme, irrespective of its localization, has been coined: membrane glutamate carboxypeptidase (Rawlings and Barrett 1997) or glutamate carboxypeptidase II (Luthi-Carter et al. 1998) .
GCPII is a class II membrane glycoprotein with an apparent molecular mass of 94±100 kDa. Class II membrane proteins typically have a short cytoplasmic amino terminus, a single membrane-spanning domain and a large extracellular domain. Apart from the membrane-bound version of GCPII, mRNA coding for an alternatively spliced variant, PSM¢, has been found in human prostatic cancer cells (Su et al. 1995) . The protein coded by the variant is truncated at the N-terminus, lacks the signal sequence and transmembrane domain of GCPII and, as it is a cytosolic protein, should not be glycosylated (Hart 1992) . Normal human prostate expresses more mRNA coding for PSM¢ than mRNA for membrane-bound GCPII. This ratio is reversed upon malignancy (Su et al. 1995) .
No direct structural data for PSMA (GCPII) are available at present. Israeli et al. (1993) and Mahadevan and Saldanha (1999) identi®ed sequence similarity of PSMA to the transferrin receptor. Rawlings and Barrett (1997) proposed a model for human GCPII based on a region of similarity to the M28 peptidase family (metallopeptidases). They predict six individual domains in the PSMA molecule: a short cytoplasmic tail, a transmembrane domain and four large extracellular domains. Based on homologies to aminopeptidases from Streptomyces griseus and Vibrio proteolyticus, the region spanning amino acids 274±587 was proposed to represent the catalytic domain. These proteases have a binuclear Zn 2+ centre at the active site in which the two zinc atoms share a bridging carboxylate ligand. Speno et al. (1999) used site-directed mutagenesis to analyse ®ve putative zinc ligands in the molecule of GCPII. Substitutions of these amino acids led to severe disruption of GCPII enzymatic activity. It is consistent with the assignment of these residues and suggests that GCPII is indeed structurally similar to the other M28 peptidase family members.
Even though GCPII represents a potentially very important target for therapeutic intervention of neurological disorders, the enzyme is relatively poorly characterized. The puri®ca-tion of the full-length GCPII from the brain or prostate cells is dif®cult and yields low amounts of the enzyme (Slusher et al. 1990 ). Moreover, a reliable and high throughput enzymatic assay for the enzymatic characterization of GCPII and large scale inhibitor testing is lacking. The current assay based on the hydrolysis of radiolabeled NAAG and the detection of free labelled Glu separated by ion-exchange chromatography is troublesome, time-consuming and poorly reproducible. Very little is known about different forms of GCPII expressed in membranes of different cells and about the structure and activity of the soluble form of GCPII (PSM¢), expressed in the normal human prostate.
In this paper we describe the preparation and enzymatic characterization of milligram quantities of active, recombinant human GCPII and the development of a new highthroughput assay to screen potential inhibitors. We also describe the role of glycosylation for the enzymatic activity, and analysis of the substrate speci®city and inhibition of the enzyme.
Experimental procedures
Expression plasmids A PCR approach was used to amplify human GCPII extracellular portion (amino acids 44±750; Rawlings and Barrett 1997) . Primers used were RNAEXST (XhoI) 5¢-ATTCTCGAGTCATTAGGCTA CTTCACTCAAAG-3¢ and FNAEXX (BglII) 5¢-AAACTCGAGA-GATCTAAATCCTCCAATGAAGC-3¢ (newly introduced restriction sites are in italic). Template ampli®cation (pcDNA3.1/GCPII) was performed using Pfu-polymerase (Promega, Madison, WI, USA) according to the manufacturer's protocol. A PCR reaction began with an initial denaturation step (94°C for 5 min), followed by 30 cycles of ampli®cation (1 min at 94°C, 1 min at 58°C, and 4 min at 72°C), and ended with a ®nal extension step (72°C for 5 min). A 2130-bp PCR fragment was puri®ed by gel electrophoresis, digested with BglII/XhoI and cloned into pMT/BiP/V5-His A (Invitrogen, Carlsbad, CA, USA) previously digested with the same set of enzymes. The resulting plasmid has been designated pMNAEXST.
A similar approach was used to clone other GCPII variants. The following primer pairs were employed to amplify GCPII fragments depicted in Fig. 1 : FNA59E (BglII) 5¢-AAAAGATCTGCATTTTT-GGATGAATTG-3¢ together with RNAST (NotI) 5¢-AAAGCGGC-CGCCTATTAGGCTACTTCACTCAAAG-3¢ for NA59E; and FNA59I (KpnI) 5¢-AAAGGTACCAATAATGGCATTTTTGGATG AATTG-3¢ together with RNAST (NotI) for NA59I. The NA59I fragment is expressed intracellularly and is cloned into pMT/V5-His A vector (Invitrogen), the two other fragments were cloned into pMT/BiP/V5-His A.
Identities of all sequences have been veri®ed by dideoxynucleotide terminated sequencing using an ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit v2.0 (Perkin-Elmer Corporation, Norwalk, CT, USA) and an ABI Prism 310 Genetic Analyzer (Perkin-Elmer Corporation).
Transfection of insect cells and stable cell line generation Schneider's S2 cells (Invitrogen) were maintained in SF900II medium (Gibco, Rockville, MD, USA) supplemented with 10% fetal bovine serum (FBS; Sigma) at 22±24°C. Before transfection, the cells were seeded in a 35-mm dish and grown until they reached a density of 2±4´10 6 cells/mL. The cells were co-transfected with 19 lg of pMNAEXST and 1 lg of a pCoHYGRO selection vector (Invitrogen) using a kit for calcium phosphate-mediated transfection (Invitrogen). The calcium phosphate solution was removed 16 h post-transfection and fresh SF900II medium supplemented with 10% FBS was added (a complete medium). The cells were grown for additional 2 days and then the medium was replaced with the complete medium containing 400 lg/mL Hygromycin B (Invitrogen). The selection medium was changed every 4 days. Extensive cell death of non-transfected cells was evident after about 1 week and cells resistant to Hygromycin B started grow out 3±4 weeks posttransfection.
rhGCPII large scale expression The hygromycin-resistant cells were seeded in 100 mL expression medium [SF900II medium supplemented with 1 mL Chemically De®ned Lipid Concentrate (Gibco) and 2 mL Yeastolate Ultra®ltrate (Gibco)] in a spinner¯ask (250 cm 3 ; Bellco Glass Inc., Vineland, NJ, USA) at density 2´10 6 cells/mL. The spinner was incubated at 24°C with a constant stirring rate 100 rpm until the cells reached a density of 10´10 6 cells/mL. At this point, the cell suspension was transferred into a larger spinner¯ask (3 L; Bellco), 400 mL expression medium was added, and the cells were grown to a density 8´10 6 cells/mL under the same conditions. Then, 500 lM CuSO 4 (Sigma) was used to induce rhGCPII expression. A stirring rate was increased to 130 rpm and incubation continued additional 6±8 days. Five milliliters of 20% D-(+)-glucose (Sigma) and 2 mL 200 mM L-glutamine (Sigma) were added to the cell suspension on days 2 and 5. The cells were harvested by centrifugation at 1600 g for 10 min followed by the second centrifugation step at 3400 g for 15 min. The conditioned medium was frozen and stored at ) 70°C until further use.
rhGCPII puri®cation
The conditioned medium (0.5 L) was dialysed against 20 mM Tris± HCl, pH 6.7, for 3 days at 4°C. The dialysing buffer was changed every 24 h. QAE-Sephadex A50 (4 g, Pharmacia) was pre-equilibrated in 20 mM Tris±HCl, pH 6.7, and added to the conditioned medium. Resulting slurry was stirred for 20 min at room temperature and ®ltered through a sintered glass ®lter. Retained QAESephadex was washed with 100 mL 20 mM Tris±HCl, pH 6.7. 2´300 mL of pooled¯ow-through fractions were directly applied on a Source 15S column (HR10/10, Amersham Pharmacia Biotech AB, Uppsala, Sweden) pre-equilibrated with 20 mM Tris±HCl, pH 6.7 (buffer A), at room temperature. The rhGCPII was eluted with a linear 0±0.5 M NaCl gradient in buffer A. The fractions containing rhGCPII were pooled, mixed with an equal volume of buffer C (100 mM Tris±HCl, 0.8 M NaCl, 2 mM CaCl 2 , 2 mM MnCl 2 , pH 7.4), and loaded on the Lentil Lectin-Sepharose (Sigma, St Louis, MO, USA) column (C10/10, Pharmacia) equilibrated with 20 mM Tris±HCl, 0,5 M NaCl, 1 mM CaCl 2 , 1 mM MnCl 2 , pH 7.4 (buffer D), at 10°C. The column was extensively washed with 40 mL of buffer D, and rhGCPII was eluted with 60 mL of 20 mM Rawlings and Barrett (1997) . LP, leader peptide; CD, putative catalytic domain; polypeptides spanning amino acids 44±150, 151±274, and 587±750, domains of unknown function. (b) NAAG hydrolysing activity of the expressed fragments. Secretion: (+), protein secreted into medium; (±), protein expressed intracellularly. (c) Western blot analysis of the fragments expression. Lane A, molecular weight marker; lane I, conditioned medium, NAEXST fragment; lane II, conditioned medium, NA59E fragment; lane III, 10 6 cells, NA58I fragment. Proteins were resolved on 11% SDS±PAGE, electroblotted on a PVDF membrane, immunodetected by antirhGCPII mouse monoclonal antibody at 1 : 250 dilution followed by incubation with 1 : 4000 alkaline phosphatase conjugated goat antimouse antibody (Bio-Rad) and developed using NBT/BCIPmixture.
Tris±HCl, 0.5 M NaCl, 0.3M Met-a-D-Man (Sigma), pH 7.4. The eluate was dialysed against 20 mM Tris±HCl, pH 8.5, overnight at 10°C, and then applied on a MonoP column (HR5/10, Pharmacia) equilibrated with 20 mM Tris±HCl, pH 8.5. The protein was eluted with Polybuffer 96 (Pharmacia) adjusted to pH 6.7 with HCl.
Preparation of rat brain synaptic membrane fraction Brain GCPII synaptic membrane fractions from frozen rat brains were prepared as previously described (Robinson et al. 1987) .
Monoclonal antibody
Monoclonal antibodies were prepared according to an established protocol (Langone and Van Vunakis 1986). Brie¯y, Balb/c mice were immunized by intraperitoneal injections of purifed rhGCPII in phosphate-buffered saline (PBS; 40 lg/100 lL) mixed with equal volume of incomplete Freund's adjuvant in 3-week intervals. Hybridomas, prepared by fusion of immune spleen cells and Sp/0 myeloma cells, were cloned by limited dilution and assayed for production of rhGCPII-speci®c antibodies by enzyme-linked immunosorbent assay. Positive clones were expanded and conditioned medium used at 1 : 250 dilution on immunoblots.
SDS±PAGE and western blotting
Analysed protein samples were resolved by reducing, 0.1% sodium dodecyl sulphate (SDS), 11% polyacrylamide gel electrophoresis (PAGE). Following SDS±PAGE, gels were either silver-stained or electroblotted on a polyvinylidene di¯uoride (PVDF) membrane.
The membrane was blocked with 5% non-fat milk in PBS for 1 h at room temperature. After two washes with 0.1% Triton X-100 in PBS, the blot was incubated with anti-rhGCPII mouse monoclonal antibody at 1 : 250 dilution in 5% non-fat milk, 0.1% Triton X-100 in PBS overnight. The membrane was washed 3´15 min and incubated with 1 : 4000 alkaline phosphatase-conjugated goat antimouse antibody (Bio-Rad Laboratories, Hercules, CA, USA) for 2 h. After three washes, the blot was developed using an NBT/BCIP mixture.
Carboxypeptidase activity Radioenzymatic assays using 3 H-NAAG (radiolabelled on the terminal glutamate) were performed as described previously (Robinson et al. 1987) , with minor modi®cations. Brie¯y, 50 mM Tris±HCl, pH 7.4 at 37°C, 1 mM CoCl 2 , and 10 lL rhGCPII were pre-incubated for 15 min at 37°C in a ®nal volume 450 lL. Then, 50 lL mixture of 4.95 lM ÔcoldÕ NAAG (Sigma) and 50 nM 3 H-NAAG (51.9 Ci/mmol; New Life Science, Boston, MA, USA) were added to each tube and incubation continued for 20 min. The reaction was stopped with 0.5 mL ice-cold 200 mM sodium phosphate, pH 7.4, cleaved glutamate was separated from the unreacted substrate by ion exchange chromatography, and measured by liquid scintillation.
Dipeptidylpeptidase IV-like activity Dipeptidylpeptidase IV (DPP IV) activity was determined bȳ uorescent analysis of the Gly-Pro-AMC hydrolysis on a PerkinElmer LS50B¯uorimeter (excitation at 380 nm, emission at 460 nm). Assays were initiated by the addition of the rhGCPII (10 lL, 60 lg/mL) to the buffered substrate solutions (12 lM Gly-Pro-AMC, 5 mM NaCl and 50 mM glycine pH 8.5 or 50 mM Tris±HCl, pH 7.7) in a total reaction volume 2 mL and followed for 15 min at 37°C. C6 rat glial cells (20 lL, 4´10 6 cells/mL in PBS) were used as a positive control (Sedo et al. 1998) .
Synthesis of peptide libraries
The substrates of general formulae Ac-Xxx-Glu-OH or Ac-AspXxx-OH were prepared by solid phase peptide synthesis on a 2-chlorotritylchloride resin (Calbiochem-Novabiochem AG, Laeufel®ngen, Switzerland) using Fmoc/Bu t protection and TBTU/DIEA coupling strategy according to Barlos et al. (1991) . N-terminal acetylation was accomplished with acetic anhydride in presence of DIEA. A mixture of 95% tri¯uoroacetic acid and 5% water was used for a ®nal cleavage from the resin. The peptides were evaporated and lyophilized from acetic acid, 50% aquaeous acetonitrile and water. Dipeptides comprising Cys, Asn, Gln, His, Met or Arg were cleaved with a mixture of 90% tri¯uoroacetic acid, 5% water, 2.5% triisopropylsilane and 2.5% ethanedithiol, extracted with diethylether, evaporated and lyophilized as described above. The peptides were analysed by HPLC and characterized by amino acid analysis and FAB-MS.
Detection of reaction products by o-phthaldialdehyde modi®cation
One hundred milligrams of o-phthaldialdehyde (OPA; Sigma) was dissolved in 625 lL methanol and transferred into 50 mL of 0.8 M sodium borate, pH 10.0, and 50 lL mercaptoethanol (Sigma) was added. This OPA solution (250 lL) was added to an equal volume of the reaction mixtures, vortexed and left at room temperature for 10 min. Fluorescence was measured on a Perkin-Elmer LS-3B uorimeter (excitation at 330 nm, emission at 450 nm). Hydrolysis of an Ac-Asp-Pro was determined using amino acid analysis.
Screening of potential substrates
The individual compounds were dissolved in 10% dimethylsulphoxide (DMSO; Sigma) in water. One microliter of rhGCPII (60 lg/mL) was added to the buffered substrate solutions (500 lM individual compound, 5 mM NaCl, 50 mM MOPS, pH 7.4). The reactions were allowed to proceed for 15 h at 37°C. The hydrolysis products, with the exception of proline, were determined spectrouorometrically using derivatization with OPA (Sigma).
K m determination
Enzyme kinetics of novel substrates were analysed by highperformance liquid chromatography (HPLC) with¯uorometric detection (excitation 330 nm, emission 450 nm). The instrument used was Spectra-Physics SP8800, and reaction products were separated on a C18(2) Luna column (Phenomenex, 25´4.6 mm). Glutamate and methionine were measured as¯uorescent derivatives after a pre-column OPA derivatization (see above). A Kratos FS 960 uorescence detector (Krantos Analytical Instruments, Hofheim, Germany) together with an SP4400 integrator (Spectra-Physics, Mountain View, CA, USA) were used for peak quanti®cation. Collected data were analyzed using EnzFitter curve-®tting package (Biosoft, Cambridge, UK). Typically, a nanomolar enzyme preparation in buffer 20 mM MOPS containing 10 mM NaCl, pH 7.4 was used to hydrolyse 5±2000 lmole/L concentration of the analysed substrate for 30 min at 37°C. The relative turnover of the substrate did not exceed 20%. A total of 8±12 concentration points were used for a single determination.
rhGCPII Deglycosylation
One microliter of PNGase F (NEB, 1000 U/lL) was used to deglycosylate 10 lg of native rhGCPII in 20 mM MOPS, 20 mM Tris±HCl, pH 8.5. The deglycosylation took place at 37°C for 15 h in total volume of 100 lL.
Recombinant expression of non-glycosylated rhGCPII S2 cells stably expressing rhGCPII were grown in 60-mm tissue culture plates in SF900II medium supplemented with 10% FBS. At the density 5´10 6 cells/mL, tunicamycin (Sigma, 1 mg/mL stock solution in DMSO) was added to the ®nal concentration 10 lg/mL, and rhGCPII expression induced by 1 mM CuSO 4 . Cells were incubated for additional 36 h and harvested.
Preparation of cell lysates
Harvested cells were counted and centrifuged at 500 g at 4°C. The conditioned media were removed and frozen at )70°C until further use. The cells were resuspended in ice-cold TBS and re-spinned. The supernatants were discarded. The cell pellets were resuspended in 20 mM MOPS, 0.5 M NaCl, 1 mM CaCl 2 , 1 mM MnCl 2 , pH 7.4 (buffer D) to concentration 40´10 6 /mL, sonicated three times for 20 s on ice, and subjected to centrifugation at 15 000 g for 10 min; the supernatant fraction is reffered to as the cell lysate.
Separation of glycosylated and non-glycosylated rhGCPII Cell lysates were mixed with 100 lL of Lentil Lectin Sepharose (Sigma), the slurry was incubated for 20 min on ice and then centrifuged at 700 g for 5 min. The supernatant, containing nonglycosylated rhGCPII, was removed and the resin with glycosylated rhGCPII bound was washed three times with ice-cold buffer D. A total of 200 lL of 0.1 M sodium borate, pH 6.5, was used for elution of glycosylated proteins bound to the resin. NAAG hydrolysing activity and rhGCPII distribution in cell lysates, Ônon-glycosylated rhGCPIIÕ fraction and the fraction eluted with sodium borate were measured by radioenzymatic assays using 3 H-NAAG or western blot, respectively (see above).
Results

Expression of proteolytically active fragments
In order to obtain human glutamate carboxypeptidase II in quantities suf®cient for enzymological analysis, we established an ef®cient source of the recombinant enzyme. When attempts to produce the active enzyme in Escherichia coli turned out to be unsuccessful (C. Barinka et al. unpublished observation), we decided to use insect cells for the heterologous expression. Speci®cally, Drosophila expression vector in Schneider's S2 cells (Invitrogen) was chosen. The DNA sequences coding two different fragments of human GCPII, designated NAEXST (fragment I in Fig. 1 ) and NA59E (fragment II), were PCR ampli®ed, cloned into pMT/Bip/ V5-His A Drosophila expression vector in an open reading frame with a BiP signal sequence that directs the secretion of the proteins into the medium. These fragments span amino acids 44±750 and 59±750, respectively, of the mature human GCPII. The third fragment, designated NA59I (amino acids 59±750, fragment III in Fig. 1 ) was cloned into the pMT/V5-His A vector and expressed intracellularly. Figure 1 shows the fragments used for heterologous expression together with the schematic representation of the putative domains of GCPII structure, as suggested by Rawlings and Barrett (1997) . All three constructs involve the predicted proteolytic domain, homologous with the Aeromonas proteolytica and Streptomyces griseus aminopeptidases (designated CD in Fig. 1 ). As shown in Fig. 1 , all three fragments were expressed (Fig. 1c) . Only the proteins secreted to the medium show proteolytic activity (compare to Fig. 5 ). The protein I spanning amino acids 44±750 in the mature human GCPII sequence was used for further puri®cation and characterization, and is referred to as recombinant human GCPII (rhGCPII) throughout the following paragraphs.
rhGCPII puri®cation Using the BiP signal sequence, rhGCPII was secreted into the medium, and the BiP leader peptide was ef®ciently cleaved off along the secretory pathway. N-terminal sequencing of the secreted rhGCPII revealed amino acids RSKSSNEAT. The ®rst two amino acids identi®ed were coded by BglII recognition site nucleotides, and the rest of the above sequence corresponded to amino acids 44±50 of human GCPII.
rhGCPII was puri®ed by combination of ion-exchange chromatography, Lentil Lectin-Sepharose chromatography and chromatofocusing, as described in the Experimental Procedures section. The overall puri®cation was 12-fold with 36% recovery, yielding 42 mg of pure rhGCPII from 1 L of medium. The enzyme purity was assessed by silver staining of reducing 11% SDS±PAGE gels. SDS±PAGE of pooled fractions at various stages in the puri®cation is shown in Fig. 2 . The ®nal purity of the enzyme was higher than 98% as seen from the mass spectrometry analysis (data not shown). The protein purity was further documented by the fact that the enzyme readily crystallizes from concentrated preparations (unpublished observation).
Analysis of rhGCPII substrate speci®city
Taking advantage of the pure recombinant enzyme, a panel of dipeptides of general formulae Ac-L-Xxx-L-Glu or Ac-LAsp-L-Xxx (Xxx standing for any naturally occurring amino acid) was tested for the cleavage by rhGCPII. Liberation of a C-terminal amino acid residue was determined uorometricaly exploiting OPA derivatization (Lindroth and Mopper 1979) of a liberated amino group. Identities of amino acids hydrolysed were con®rmed by an amino acid analysis (data not shown).
The results of the substrate speci®city analysis using a panel of dipeptides are schematically presented in Fig. 3 . Ac-Asp-Glu (NAAG, a naturally occurring substrate in the brain), Ac-Glu-Glu and Ac-Ala-Glu, were identi®ed as substrates of rhGCPII in the ®rst screen using set of dipeptides of general formula Ac-Xxx-Glu. To analyse the requirement for the amino acid at the C-terminus of the substrate, we synthesized the second panel of protected dipeptides with the general formula Ac-Asp-XxxOH. In this screen, Ac-Asp-Glu and, surprisingly, Ac-Asp-Met were found to be cleaved by the enzyme (Fig. 3b) . To verify that the rhGCPII was indeed responsible for hydrolysis of the substrates, we performed control analyses in the presence of the GCPII inhibitors EDTA, PO 4 and 2-PMPA. No substrate hydrolysis could be detected with the inhibitors added (data not shown). In the light of these results, the third set of potential substrates of general formula Ac-Xxx-Met was synthesized and evaluated. In this set of dipeptides, we identi®ed Ac-Glu-Met, Ac-Asp-Met and Ac-Ala-Met as effective substrates of rhGCPII (Fig. 3c) . While the cleavage of Ac-Asp-Met merely con®rms the ®nding from the previous experiment, Ac-Glu-Met and, especially, Ac-Ala-Met represent novel substrates of GCPII.
The results shown in Fig. 3 do not provide direct comparison of the kinetics of cleavage of these substrates by the protease since the endpoint of the analysis was well beyond the linear part of the enzymatic reaction.
Kinetic analysis of newly identi®ed substrates of rhGCPII
The rate of cleavage of newly identi®ed substrates were analysed by HPLC using¯uorometric detection after a pre-column OPA derivatisation. The data are summarized in Table 2 . We have not been able to determine the kinetic constant for Ac-Ala-Glu because the initial velocities do not follow simple Michaelis±Menten kinetics, apparently due to the substrate inhibition. As the other substrates are concerned, the Met-containing dipeptides show two to three orders of magnitude decrease of the K m , while the k cat is less affected. Not surprisingly, the enzyme shows the lowest activity towards Ac-Ala-Met (a four-order of magnitude drop of k cat /K m in comparison to the originally described Ac-Asp-Glu, compare Fig. 3 (a±c) Hydrolysis of N-acetylated dipeptides of general formulae Ac-X-GluOH, Ac-Asp-XOH, and Ac-X-MetOH by the rhGCPII.1 lL rhGCPII (60 lg/mL) was added to the buffered substrate solutions (500 lM individual compound, 5 mM NaCl, 50 mM MOPS, pH 7.4). The reactions were allowed to proceed for 15 h at 37°C. The hydrolysis products were determined spectro¯uorometrically exploiting derivatization with o-phthaldialdehyde. x-axis: an amino acid at X position; y-axis: relative¯uorescence units (RFU).
The pH dependence of peptide cleavage by rhGCPII
To analyse the pH dependence, the cleavage of Ac-Asp-Glu was followed in pH range 4.0±9.5 by radiometric assay as well as by the¯uorescence measurement using Ac-Asp-Glu as a substrate and OPA detection of the liberated C-terminal amino acid (Fig. 4) . The activity shown in Fig. 4 corresponds to less than 20% turnover of the substrate. The resulting activity curve is bell-shaped with a relatively broad maximum between pH 6.0 and 8.0. The activity sharply drops at pH above 8.5 and also the activity in the pH range below 4.5 is negligible.
Dipeptidylpeptidase IV-like activity of rhGCPII Pangalos et al. (1999) reported a DPP-IV-like activity in homogenates from COS cells transiently transfected with GCPII and GCPII-like cDNAs. To analyse possible aminopeptidase activity of rhGCPII we measured hydrolysis of a typical¯uorogenic substrate of DPP-IV, the Gly-Pro-AMC (Kato et al. 1978) , by the rhGCPII. Under the conditions described in the Experimental Procedures section, we have not been able to detect any DPP-IV-like activity using excessive amounts of pure rhGCPII, while C6 rat glial cells, used as a positive control (Sedo et al. 1998) , hydrolysed Gly-Pro-AMC quite ef®ciently (data not shown).
Testing of speci®c inhibitors and comparison with the native enzyme
The availability of a pure, recombinant form of GCPII and the development of a¯uorescent activity assay is especially advantageous for the analyses of the structure±activity relationships and for large-scale inhibitor testing. To document the usefulness of our recombinant protein and the assay, we tested the inhibitory activity of a panel of potent GCPII inhibitors, 2-PMPA (Jackson et al. 1996) and other compounds, summarized in Table 2 . To determine whether rhGCPII correctly represents pharmacological activity of individual forms of GCPII described in rat brain, in membrane fractions of LNCaP, human prostate or transiently transfected COS cells, a set of experiments was carried out. We found that the K i values determined for the rhGCPII are comparable to those determined using GCPII isolated from the rat brain. The data are summarized in Table 2 . When using 2-PMPA, a very potent and speci®c inhibitor, the IC 50 values show no signi®cant difference. The IC 50 values for the less speci®c inhibitors, e.g. quisqualate and phosphate, are shifted towards lower values, i.e. the inhibitors are apparently more potent when puri®ed enzyme is used for the assay, which could be explained by non-speci®c binding of these inhibitors to the other proteinaceous components of the synaptosomal membrane preparations.
Activities of GCPII identi®ed in normal and cancer cells: role of glycosylation
It has been shown that GCPII exists in two different forms ± as a glycosylated type II membrane protein and a soluble cytosolic protein (Grauer et al. 1998; Tiffany et al. 1999) . The two forms result from alternative splicing of mRNA (Su et al. 1995) , and the N-terminal amino acid of the soluble form is believed to be Ala 60 of the Ôfull-lengthÕ transmembrane protein (Grauer et al. 1998) . As it is a cytosolic protein, the shorter form should not be glycosylated (Hart 1992) . To test the in¯uence of glycosylation on the rhGCPII carboxypeptidase activity, we deglycosylated the rhGCPII using PNGase F. Interestingly, deglycosylation of the native protein under conditions described in the Experimental Procedures section completely abolished its carboxypeptidase activity (Fig. 5, line 6 ).
To verify this surprising observation, we expressed a ÔcytoplasmicÕ variant of GCPII (PSM¢; Su et al. 1995; Tiffany et al. 1999) , lacking the signal sequence and the Fig. 4 pH dependence of NAAG cleavage by rhGCPII. The following buffers, together with 10 mM NaCl, were used in 50-mM concentrations spanning a pH range of 4±9.5: acetate, pH 4.0±5.0; 2-(N-morpholino)-ethanesulphonic acid, pH 5.5±6.5; MOPS, pH 7.0±8.0; Tris±HCl, pH 8.5±9.5. The substrate cleavage was followed by scintillation spectrometry measuring released 3 H-Glu separated by ion-exchange chromatography (see Experimental procedures). Typical substrate conversion did not exceed 20%. The kinetic values were determined using the detection of reaction products by OPA as described in Experimental Procedures. a These values were determined by the radioenzymatic assay using 3 H-NAAG as described (Tiffany et al. 1999 ). b K m value was below the detection limit of the OPA method.
Analysis of recombinant human glutamate carboxypeptidase II 483 transmembrane domain. This construct, except for the N-terminal methionine, thus corresponds to the protein that has been identi®ed in the cytosol of normal human prostatic cells. Upon transfection into insect cells, we were able to detect expression of the corresponding protein product using mouse monoclonal antibodies, but no activity was observed (Fig. 5, lane 5) .
To further strengthen the claim that glycosylation is essential for rhGCPII NAAG hydrolysing activity, we expressed rhGCPII in presence of tunicamycin, which potently inhibits the ®rst step in N-glycosylation pathway. As seen on western blot (Fig. 5) , the apparent molecular weight of rhGCPII expressed in medium suplemented with tunicamycin (10 lg/mL) was lower than that of the protein produced in medium without the inhibitor, and apparently identical with rhGCPII deglycosylated by PNGase F in vitro (Fig. 5, compare lanes 2 and 6) . Residual activity detected in lysates from cells cultured in the presence of tunicamycin suggests that N-glycosylation inhibition was not complete. Indeed, after the separation of non-glycosylated and glycosylated proteins by af®nity chromatography on LentilLectin Sepharose (see Experimental procedures), the NAAG hydrolysing activity could only be detected in the fraction bound to, and subsequently eluted from, the resin (Fig. 5,   lane 4) . As Lentil-Lectin speci®cally binds to mannose residues in sugar chains present on glycoproteins, all the NAAG hydrolysing activity could thus be attributed to the glycosylated protein.
Discussion
The ®rst task in enzymological analysis of any medically relevant enzyme is to establish a reliable source of active, pure protein for further investigation. GCPII was identi®ed as an important regulatory enzyme in the late 1980s (Robinson et al. 1987) . Slusher et al. (1990) published the puri®cation and partial enzymological characterization of rat brain GCPII in 1990. The enzyme has been identi®ed in multiple prostate cell lines and in prostate tissues of eight mammalian species (Tiffany et al. 1999) and partial pharmacological and kinetic characterization of the enzymic cleavage of N-acetyl-AspGlu has been provided. Tiffany et al. (1999) reported virtual identity of GCPII from the rat brain and from the prostate (documented by the sensitivity towards inhibitors and similar kinetic values for the substrate cleavage). The activity of the soluble, cytosolic form of prostate GCPII (PSM¢) was signi®cant and the kinetics of substrate cleavage suggested two catalytic sites of this form of the enzyme. Recently, The IC 50 values were determined by the radioenzymatic assay using 3 H-NAAG as described. Lodge et al. (1999) reported expression of the human GCPII in insect cells using a baculovirus vector. The system was apparently capable of producing enough recombinant protein for the production of monoclonal antibodies. However, no further enzymological or structural characterization of the protein was provided.
In an attempt to provide a reliable source of a highly pure recombinant protein for enzymological characterization, inhibitor testing and structural analysis, we set out to express the extracellular domain of human brain GCPII in bacterial and insect cells expression systems. In E. coli, massive amounts of recombinant protein of the correct molecular weight were produced. However, all the recombinant protein was present in insoluble inclusion bodies. No refolding conditions yielded any signi®cant proteolytic activity, suggesting that bacterial cells do not provide the post-translational machinery necessary for correct folding and activity. As the second choice, we employed a relatively novel insect cell expression system using Drosophila Schneider's S2 cells. Altogether, three GCPII variants were cloned and transfected into S2 cells. Both variants secreted into medium showed marked NAAG hydrolysing activity, while the NA59I construct, expressed intracellularly, was completely inactive.
To date, the only assay available for the screening of the activity of GCPII has been a radioenzymatic assay using tritiated Ac-Asp-[ 3 H]Glu (Robinson et al. 1987) . It is a very sensitive assay, enabling determinations of nanomolar concentrations of cleaved glutamate. On the other hand, the assay is not useful for high-throughput testing of large inhibitor series. Moreover, the handling and disposing radiolabelled substrate represents an additional burden for the experimenter. We therefore designed a simple assay based on the chemical modi®cation of the newly liberated amino acid of the N-terminally blocked substrate by ā uorophor and subsequent¯uorometric determination. Our system exhibits an approximately 100-fold lower sensitivity in comparison with the radioenzymatic one. However, because of the availability of highly active, pure recombinant GCPII, the sensitivity does not represent a major concern. Moreover, the new assay is less labourious, more reproducible and possible to automate for the high-throughput screening and analysis.
To determine whether rhGCPII correctly represents the pharmacological activity of different forms of GCPII described in individual tissues (rat brain, membrane fractions of LNCaP, human prostate or transiently transfected COS cells), a set of inhibition values was determined for the rhGCPII and found to be comparable with the values determined using GCPII isolated from the rat brain (see Table 2 ). For 2-PMPA, a very potent and speci®c inhibitor of GCPII, the IC 50 values show no signi®cant difference. The assay using puri®ed recombinant enzyme yields lower IC 50 values for the less speci®c inhibitors, such as quisqualate and phosphate. We speculate that phosphate and quisqualate probably bind to other proteins in the synaptosomal membranes and thus higher concentrations are needed to reach 50% inhibition of the enzyme.
The usefulness of the system was further documented by testing a series of peptide substrates of GCPII, and determination of the pH optimum of the enzymatic cleavage. Using libraries of all possible dipeptides of general formulae Ac-Asp-Xxx, Ac-Xxx-Glu and Ac-Xxx-Met we identi®ed four new effective substrates of GCPII: Ac-Glu-Met, Ac-AspMet, Ac-Ala-Glu and Ac-Ala-Met. Interestingly, the Metcontaining dipeptides are the ®rst examples of a substrate without C-terminal Glu for this enzyme. Moreover, the Ac-Ala-Met substrate surprisingly lacks the carboxyl moiety in the side chain. In order to rule out possible oxidation of the side chain sulphur atom of the methionine, we analysed the presence of a sulphonyl group by mass spectrometry. No signi®cant oxidation of the Met residue was observed suggesting that negative charge at the side chain of the C-terminal amino acid is not a necessary prerequisite for the substrate to be hydrolysed. This ®nding might be important also for the design of speci®c inhibitors of GCPII.
Detailed enzymologic analysis of newly identi®ed substrates reveals at least two orders of magnitude higher K m values and thus weaker binding for the compounds containing Met as a C-terminal residue, while the corresponding k cat values are less affected. The speci®c activity of rhGCPII (k cat /K m ) against these substrates decreases in the sequence Ac-Glu-Met, Ac-Asp-Met and Ac-Ala-Met, re¯ecting thus the requirement for the negatively charged residue in the substrate for the productive binding to the enzyme binding cleft. There are several amino acids with basic side chain residues that might be positioned in the vicinity of the substrate binding site of GCPII and form thus favourable electrostatic interactions with negatively charged residues of the substrate (D. Mahadevan et al., manuscript in preparation). Speno et al. (1999) mutated several residues thought to be important for catalysis and ligand binding. Mutation of residues R463, R536 and K545 increased the K m values for Ac-Asp-Glu several times, showing thus the importance of electrostatic interactions for the proper substrate binding. The surprising ®nding that substrates containing Met at their C-terminus could be cleaved by the enzyme, albeit less ef®ciently, will have to be analysed in structural terms once a three-dimiensional structure of the enzyme becomes available.
The pH dependence of GCPII seems to be similar to other carboxypeptidases, namely the carboxypeptidase A and glutamate carboxypeptidase G1 from Pseudomonas. The sharp fall of the activity in the pH range above 8.0 seems to be caused by ionization of the critical residues binding catalytic Zn 2+ ion. Recently, Pangalos et al. (1999) reported a novel variant of human GCPII called NAALADase like peptidase, mapped to chromosome 11 and expressed within discrete brain areas. The authors analysed the activity of this novel variant and compared it to the previously described GCPII from rat brain (denominated NAALADase I) and NAALADase-like enzyme from human ileum (NAALADase L). They report that the novel enzyme as well as ÔconventionalÕ GCPII exhibits dipeptidyl peptidase IVactivity, as shown by analysing lysates of COS cells transiently transfected by the corresponding cDNAs. In an attempt to con®rm this surprising observation, we tested the activity of rhGCPII with a model substrate GlyPro-AMC. No signi®cant hydrolysis of the substrate was observed with pure recombinant human GCPII. Abbott et al. (2000) point out that a DPP IV-like activity of a zinccontaining carboxypeptidase is rather surprising. Because Pangalos et al. (1999) used cleared lysates of transiently transfected COS cells, the apparent DPP IV activity might be attributed to the up-regulation of an endogenous protease, perhaps ®broblast-activating protein (Wesley et al. 1999) .
Several authors have shown the presence of mRNA corresponding to the cytosolic, truncated form of GCPII in prostate cells. Indeed, the mRNA coding for cytosolic form of GCPII, PSM¢, is more prevalent in the normal prostate than the mRNA for membrane-bound form (Su et al. 1995) . These authors showed the presence of an alternatively spliced GCPII mRNA that lacks 266 nucleotides at the 5¢-end (including ATG and the transmembrane domain) and should thus correspond to a cytosolic protein (Heston 1997).
While there is solid evidence for alternatively spliced mRNA corresponding to the PSM¢ in the cytosol of prostate cells, the existence and activity of the corresponding truncated cytosolic protein has not been consecutively proven. Grauer et al. (1998) isolated PSM¢ from the lysate of LNCaP cells using monoclonal antibodies against various domains of PSMA. The cells were fractionated and PSM¢ localized to the cytoplasm. The protein was puri®ed but no analysis of the activity was provided. Tiffany et al. (1999) separated cytosolic and membrane-bound forms of GCPII from prostate LNCaP cells and using fractionated cell lysates showed proteolytic activity of both forms.
In an attempt to analyse the activity of a truncated, intracellular version of GCPII (corresponding to PSM¢) we have attempted to express the DNA coding for the corresponding fragment lacking the signal sequence and transmembrane domain of GCPII (see Fig. 1 ). This truncated mutant should have Ala 60 as the amino acid following the start methionine. The NA59E, one of two variants of GCPII that provided active protein upon expression in Drosophila cells, is of the same length as the putative PSM¢ variant. However, intracellular expression of this DNA construct in insect cells yields no detectable NAAG-hydrolysing activity.
It could be argued that a cytosolic form of GCPII would probably not be glycosylated (Hart 1992; Lodge et al. 1999) and might thus differ in both structure and activity from the full-size, membrane-anchored form of the enzyme. It is interesting to note in this context that intracellular concentration of phosphate, an effective inhibitor of GCPII, is approximately 1 mM, i.e. almost one or two orders of magnitude above the corresponding K i value.
In an in vitro experiment, we show that the deglycosylation of the rhGCPII in vitro using a peptide : N-glycosidase F in trans renders it completely inactive (see Fig. 5 ). In order to con®rm this observation, we expressed rhGCPII in insect cells as a non-glycosylated protein, blocking N-linked protein glycosylation with tunicamycin. The majority of the rhGCPII produced in the presence of tunicamycin was not glycosylated (as shown on af®nity chromatography using Lentil-Lectin) and was completely inactive (Fig. 5, lane 3) . Taken together, these data seem to suggest that the putative truncated, soluble cytosolic form of GCPII might not be a proteolytically active species.
In conclusion, the recombinant expression system here described enables production of an active recombinant protein and its enzymological characterization that might pave the way to the structural characterization of this important pharmaceutical target and development of new potent inhibitors.
rimeter and Ivan Hilgert for anti-GCPII antibodies. This work (performed under the research project Z4055 905) was supported by an International Research Scholar's Award from the Howard Hughes Medical Institute (HHMI 75195-54081) to J.K., grant IAA5055108 from the Grant Agency of the Academy of Science of the Czech Republic and by a research support from Guilford Pharmaceuticals.
